GoAI
Get started
Tenon Medical, Inc. logo

Tenon Medical, Inc.

TNON

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$6.83

−$0.24 · -3.39%

Aug 21, 4:00 PM ET

TNON company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

69

Undervalued

Momentum

17

Strong Down

Sentiment

54

Mixed

Risk resilience

28

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Steven Foster
Listed since
Apr 27, 2022
Employees
26

Market position

Day range

Current $6.83

52-week range

Current $6.83

Open
$7.20
Previous close
$7.07
Volume
500.56K
0.07× average
Average volume
7.28M
Average daily volume
Market cap
3.39M USD
Beta
1.4
Market reference 1
50-day average
$9.9425
-31.31% below average
200-day average
$25.5554
-73.27% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.41M USD
EV / EBITDA
-0.28×
Earnings yield
-178.72%
Free cash flow yield
-156.83%

Profitability & efficiency

Return on equity
-249.13%
Return on assets
-116.69%
Return on invested capital
-166.39%

Financial health

Current ratio
2.11×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends513%-1276%-3064%-4852%Gross margin, FY2021: 65.63%Gross margin, FY2022: -92.76%Gross margin, FY2023: 42.38%Gross margin, FY2024: 52.21%Gross margin, FY2025: 59.79%Operating margin, FY2021: -4038.13%Operating margin, FY2022: -2709.84%Operating margin, FY2023: -537.12%Operating margin, FY2024: -420.08%Operating margin, FY2025: -324.34%Net margin, FY2021: -4405.00%Net margin, FY2022: -2737.63%Net margin, FY2023: -532.14%Net margin, FY2024: -417.24%Net margin, FY2025: -318.36%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 65.63%. Gross margin FY2022 -92.76%. Gross margin FY2023 42.38%. Gross margin FY2024 52.21%. Gross margin FY2025 59.79%. Operating margin FY2021 -4038.13%. Operating margin FY2022 -2709.84%. Operating margin FY2023 -537.12%. Operating margin FY2024 -420.08%. Operating margin FY2025 -324.34%. Net margin FY2021 -4405.00%. Net margin FY2022 -2737.63%. Net margin FY2023 -532.14%. Net margin FY2024 -417.24%. Net margin FY2025 -318.36%.

Income trends

Revenue

3.94M USD+20.35%

Operating income

−12.79M USD+7.08%

Net income

−12.56M USD+8.17%
Income trends across reported periods6.23M USD−2.91M USD−12.06M USD−21.2M USDRevenue, FY2021: 160K USDRevenue, FY2022: 691K USDRevenue, FY2023: 2.93M USDRevenue, FY2024: 3.28M USDRevenue, FY2025: 3.94M USDOperating income, FY2021: −6.46M USDOperating income, FY2022: −18.73M USDOperating income, FY2023: −15.73M USDOperating income, FY2024: −13.77M USDOperating income, FY2025: −12.79M USDNet income, FY2021: −7.05M USDNet income, FY2022: −18.92M USDNet income, FY2023: −15.58M USDNet income, FY2024: −13.67M USDNet income, FY2025: −12.56M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 160K USD. Revenue FY2022 691K USD. Revenue FY2023 2.93M USD. Revenue FY2024 3.28M USD. Revenue FY2025 3.94M USD. Operating income FY2021 −6.46M USD. Operating income FY2022 −18.73M USD. Operating income FY2023 −15.73M USD. Operating income FY2024 −13.77M USD. Operating income FY2025 −12.79M USD. Net income FY2021 −7.05M USD. Net income FY2022 −18.92M USD. Net income FY2023 −15.58M USD. Net income FY2024 −13.67M USD. Net income FY2025 −12.56M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue3.94M USD3.28M USD2.93M USD691K USD160K USD
Cost of goods sold1.59M USD1.57M USD1.69M USD1.33M USD55K USD
Gross profit2.36M USD1.71M USD1.24M USD−641K USD105K USD
Research and development2.15M USD2.6M USD3.16M USD2.83M USD1.72M USD
Selling, general, and administrative13M USD12.87M USD13.81M USD15.26M USD4.85M USD
Operating expenses15.15M USD15.48M USD16.97M USD18.08M USD6.57M USD
Interest expense—34K USD21K USD354K USD621K USD
Depreciation and amortization530K USD655K USD426K USD289K USD114K USD
Operating income−12.79M USD−13.77M USD−15.73M USD−18.73M USD−6.46M USD
Net income−12.56M USD−13.67M USD−15.58M USD−18.92M USD−7.05M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-69.00%
11 comparable reports
Latest EPS result
-12.35
Estimate -8.4 · Miss by 47.02%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-1.12-13.42-25.73-38.03Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual -3.69, estimate -1.32, surprise -179.31%, Miss. Q2 2025, reported May 13, 2025: actual -35.31, estimate -34.65, surprise -1.90%, Miss. Q3 2025, reported Aug 13, 2025: actual -12.59, estimate -16.45, surprise +23.47%, Beat. Q4 2025, reported Nov 13, 2025: actual -13.99, estimate -12.95, surprise -8.03%, Miss. Q1 2026, reported Mar 19, 2026: actual -7.69, estimate -12.6, surprise +38.97%, Beat. Q2 2026, reported May 12, 2026: actual -10.84, estimate -10.68, surprise -1.55%, Miss. Q3 2026, reported Aug 13, 2026: actual -12.35, estimate -8.4, surprise -47.02%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -5.62, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.62M1.24M863.31K485.92KQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual 800K USD, estimate 901K USD, surprise -11.21%, Miss. Q2 2025, reported May 13, 2025: actual 726K USD, estimate 778K USD, surprise -6.68%, Miss. Q3 2025, reported Aug 13, 2025: actual 564K USD, estimate 909.5K USD, surprise -37.99%, Miss. Q4 2025, reported Nov 13, 2025: actual 1.17M USD, estimate 1.12M USD, surprise +4.59%, Beat. Q1 2026, reported Mar 19, 2026: actual 1.5M USD, estimate 1.38M USD, surprise +8.81%, Beat. Q2 2026, reported May 12, 2026: actual 1.38M USD, estimate 1.3M USD, surprise +6.45%, Beat. Q3 2026, reported Aug 13, 2026: actual 1.28M USD, estimate 1.54M USD, surprise -16.95%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate 1.43M USD, surprise —, Comparison unavailable.

TNON news

seekingalpha.com

Tenon Medical, Inc. (TNON) Q2 2026 Earnings Call Transcript

Tenon Medical, Inc. (TNON) Q2 2026 Earnings Call Transcript

Read source
accessnewswire.com

Tenon Medical Reports Second Quarter 2026 Financial Results

~ Second Quarter 2026 Revenue of $1.3 Million, a 127% Increase Compared to Prior Year ~ ~ Second Quarter Gross Profit of $0.8 Million, a 232% Increase Compared to Prior Year; Gross Margin of 64% ~ ~ Received FDA 510(k)…

Read source
accessnewswire.com

Tenon Medical, Inc. Announces 1:35 Reverse Stock Split

LOS GATOS, CA / ACCESS Newswire / August 6, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders,…

Read source
accessnewswire.com

Tenon Medical, Inc. Sets Date for Second Quarter 2026 Earnings

LOS GATOS, CA / ACCESS Newswire / July 30, 2026 / Tenon Medical, Inc. (NASDAQ:TNON)("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders,…

Read source
accessnewswire.com

Tenon Medical, Inc. Announces Regained Compliance with Nasdaq Stockholders' Equity Requirement

LOS GATOS, CA / ACCESS Newswire / July 20, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders,…

Read source
accessnewswire.com

Tenon Medical(R) Announces FDA 510(k) Clearance for Catamaran(R) SI Joint Fusion System

~ Updated clearance incorporates various instrument upgrades, as well as per-procedure costs, improving unit economics driven by the reclassification of certain instruments from disposable to reusable status ~ ~…

Read source

Corporate actions

Corporate action history

Stock split

Effective Aug 10, 2026

1:35

Stock split

Effective Sep 6, 2024

1:8

Stock split

Effective Nov 2, 2023

1:10

TNON peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TNON

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
14.2K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research TNON

research.disclaimer